Min, Kyoungseon Park, Kyungmoon Park, Don-Hee Yoo, Young Je 2024-01-20T08:01:50Z 2024-01-20T08:01:50Z 2022-01-25 2015-01 0175-7598 https://pubs.kist.re.kr/handle/201004/125887 l-DOPA (3,4-dihydroxyphenyl-l-alanine) has been widely used as a drug for Parkinson's disease caused by deficiency of the neurotransmitter dopamine. Since Monsanto developed the commercial process for l-DOPA synthesis for the first time, most of currently supplied l-DOPA has been produced by the asymmetric method, especially asymmetric hydrogenation. However, the asymmetric synthesis shows critical limitations such as a poor conversion rate and a low enantioselectivity. Accordingly, alternative biotechnological approaches have been researched for overcoming the shortcomings: microbial fermentation using microorganisms with tyrosinase, tyrosine phenol-lyase, or p-hydroxyphenylacetate 3-hydroxylase activity and enzymatic conversion by immobilized tyrosinase. Actually, Ajinomoto Co. Ltd commercialized Erwinia herbicola fermentation to produce l-DOPA from catechol. In addition, the electroenzymatic conversion system was recently introduced as a newly emerging scheme. In this review, we aim to not only overview the biotechnological l-DOPA production methods, but also to briefly compare and analyze their advantages and drawbacks. Furthermore, we suggest the future potential of biotechnological l-DOPA production as an industrial process. English SPRINGER Overview on the biotechnological production of L-DOPA Article 10.1007/s00253-014-6215-4 1 APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, v.99, no.2, pp.575 - 584 APPLIED MICROBIOLOGY AND BIOTECHNOLOGY 99 2 575 584 N scie scopus 000348770900004 2-s2.0-84925514026 Biotechnology & Applied Microbiology Biotechnology & Applied Microbiology Review TYROSINE PHENOL-LYASE IMMOBILIZED TYROSINASE ESCHERICHIA-COLI 3,4-DIHYDROXYPHENYL-L-ALANINE MUTANT CELLS GENE L-DOPA Microbial fermentation Immobilized tyrosinase Electroenzymatic system